anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a stomach-invigorating and food-retention-removing pill, and belongs to the field of Chinese pharmaceutical manufacturing. The pill comprises elecampane, areca-nuts, pericarpium citri reticulatae viride, pericarpium citri reticulatae, Coptis chinensis, rhizoma sparganii, curcuma zedoary, rheum officinale, Cyperus rotundus, golden cypress, hawthorns, Poria cocos, Pinellia ternate, rhizoma alismatis and immature bitter orange. The stomach-invigorating and food-retention-removing pill is good in effect, short in treatment course, low in price and high in cure rate, and has the major functions of treating stomach duct and abdomen distention and fullness, stomachache, abdominal distension, stomach distension, stomach fullness, food accumulation and other diseases. The stomach-invigorating and food-retention-removing pill has the effects of abating distension and fullness, washing dyspeptic disease, tonifying the spleen to remove dampness, promoting digestion and regulating the middle warmer, clearing the heat-fire, guiding stagnation, relaxing the bowels, regulating the flow of vital energy for activating stagnancy and promoting the circulation of qi to relieve distension, the effective rate is 98%, the cure rate is 80%, one to two treatment courses are needed for healing on average, three to five treatment courses are needed for patients with serious illness states, and the stomach-invigorating and food-retention-removing pill has the good market development prospect. (one treatment course lasts seven days.).
GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
The present invention relates to a method for preparing milk powder candies containing micron sugared radix codonopsitis, pearl, amber and royal jelly for lowering blood sugar and soothing nerves to eat at night. The milk powder candies are compounded from that the raw material of micron chromium nicotinic acid powder, micron amber powder, micron radix codonopsitis powder, micron pearl powder, xylitol, royal jelly freeze-drying powder, etc. which are processed by high-tech supper fine grinding is added in various traditional milk powder candies. The present invention causes the milk powder candies to have the obvious action of lowering blood sugar and also causes the milk powder candies to have the effects of improving sleep quality, resisting fatigue, enhancing immunity, tranquilizing, improving eyesight, etc. so that the milk powder candies obtain dozens of plentiful nutrient substances of protein, vitamins, mineral substances, organized enzymes, etc. and simultaneously have the actions of beautifying face, keeping youthfulness, soothing nerves and lowering blood sugar because of being added with chromium nicotinic acid called as blood sugar lowering factors. Therefore, the present invention is the method for preparing the good milk powder candies with Chinese characteristic for keeping health and promoting longevity to eat at night, which is especially designed for middle and old aged diabetics all over the world.
PROBLEM TO BE SOLVED: To provide solid cosmetics that are excellent in portability, easiness, puff-adhesion, spreading properties, coating film uniformity, fitting feeling, moisture retention effect, and long lasting makeup.SOLUTION: A solid cosmetic contains 25-40 mass% of an oil solution containing the following component (a), as well as 60-75 mass% of a powder containing the following components (b) and (C). The content of the component (a) in the entire oil solution is 70-100 mass%. Further the content of the component (c) in the entire powder is 40-90 mass%. The solid cosmetic is obtained by compression molding. (a): Fatty acid ester oil with an IOB value of 0.25 or less and with a viscosity at 25°C of 50 mPa s or less. (b): Polyurethane powder. (c): Fluorine compound treatment powder.SELECTED DRAWING: None
Compounds (I) comprising a hydrophilic tail linked via an aliphatic or aromatic hydrocarbon group to a group comprising a carbon or heteroatom free electron pair and/or pi electrons are used to prepare pharmaceutical compositions for preventing or treating cancer, pathological consequences of alcohol abuse, viral hepatitis, steatohepatitis, pancreatitis, kidney and liver diseases or reperfusion injury, as an antidote to environmental toxins and medicament intoxication, for prolonging the residence time of medicaments in vivo or for combatting the toxic side effected of chemotherapeutic agents. Compounds of formula (I) are used to prepare pharmaceutical compositions for preventing or treating cancer, pathological consequences of alcohol abuse, viral hepatitis, steatohepatitis, pancreatitis, kidney and liver diseases or reperfusion injury, as an antidote to environmental toxins and medicament intoxication, for prolonging the residence time of medicaments in vivo or for combatting the toxic side effected of chemotherapeutic agents. A-R-X (I) R : a 6-40C aliphatic or aromatic hydrocarbon group; A : a hydrophilic tail; X : a group comprising a carbon or heteroatom free electron pair and/or pi electrons. ACTIVITY : Cytostatic; Antialcoholic; Virucide; Hepatotropic; Antiinflammatory; Nephrotropic; Vasotropic; Antidote. No biological data given. MECHANISM OF ACTION : Cytochrome P450 inhibitor.
The invention discloses an externally applied hair restorer for treating alopecia areata. The hair restorer comprises, by weight, 28 to 40% of Pteris vittata Linn., 5 to 10% of valley bark, 1 to 2% of rhizoma drynariae, 1 to 2% of biota orientalis and 50 to 65% of ethanol. The preparation method for the hair restorer is as follows: 1, respectively crushing Pteris vittata Linn., valley bark, rhizoma drynariae and biota orientalis with a pulverizer into powder at normal temperature; 2, uniformly mixing crushed Pteris vittata Linn., valley bark, rhizoma drynariae and biota orientalis in proportion; 3, putting the mixed powder into a container and adding ethanol for immersion for 48 to 72 hours so as to obtain the hair restorer. The hair restorer prepared in the invention is an externally applied medicine for treating alopecia areata. The hair restorer can be directly applied on the part affected by alopecia in utilization. The hair restorer can directly reach the focus, kill skin germs and activate and nourish hair follicle, and has the advantages of fast results, good effects, convenient utilization, small toxic and side effects, etc.
A group of genetic diseases known as polycystic liver disease (PLD) are distinguished by the gradual development of fluid-filled hepatic cysts formed from cholangiocytes and commonly related to primary cilia defects. The NAD salvage pathway, which sustains cellular bioenergetics and supplies a required substrate for tasks important to rapidly multiplying cells, has a rate-limiting phase that is mediated by nicotinamide phosphoribosyltransferase (NAMPT). In this study, the efficacy and mechanisms of action of FK866, a novel, high-potency NAMPT inhibitor with a good toxicity profile, were assessed. NAMPT-siRNA and FK866 reduced NAD levels and inhibited the proliferation of PLD cells in a dose-dependent manner. Notably, this pharmacologic and siRNA-mediated suppression of NAMPT was less effective in normal cells at the same concentrations. The addition of nicotinamide mononucleotide (NMN), a byproduct of NAMPT that restores NAD concentration, rescued the cellular viability of PLD cells and verified the on-target action of FK866. In FK866-treated PLD cells, mitochondrial respiration and ATP production were impaired and reactive oxygen species production was induced. Importantly, FK866 treatment was associated with improved effects of octreotide, a drug used for PLD treatment. As a result, the use of NAMPT inhibitors, including FK866 therapy, offers the possibility of a further targeted strategy for the therapeutic treatment of PLD.
OBJECTIVE: Aortic stenosis (AS) shares pathophysiological similarities with atherosclerosis including active inflammation. CT attenuation of perivascular adipose tissue provides a measure of vascular inflammation that is linked to prognosis and has the potential to be applied to the aortic valve. We investigated perivascular adipose tissue attenuation around the aortic valve in patients with AS.
METHODS: CT attenuation was measured in the perivascular adipose tissue extending 3 mm radially and 10 mm longitudinally around the aortic valve in patients with and without AS. Associations between perivascular adipose tissue attenuation and AS disease severity, activity and progression were investigated.
RESULTS: Perivascular adipose tissue attenuation around the aortic valve demonstrated good intraobserver and interobserver repeatability (interobserver: intraclass correlation coefficient 0.977 (95% CI: 0.94, 0.99)) but was similar between patients with AS (n=120) and control subjects (n=80) (-62.4 (-68.7, -56.5) Hounsfield units (HU) vs -61.2 (-65.3, -55.6) HU, p=0.099). There were no differences between perivascular adipose tissue attenuation in patients with mild (-60.2 (-66.9, -55.1) HU), moderate (-62.8 (-69.6, -56.80) HU) or severe (-62.3 (-69.3, -55.4) HU) AS (all p>0.05), and perivascular adipose tissue attenuation did not demonstrate an association with AS severity as assessed by echocardiography or CT calcium scoring, nor with disease activity assessed by 18F-sodium fluoride positron emission tomography. Moreover, there was no association between baseline aortic valve perivascular adipose tissue attenuation and subsequent AS progression (annualised change in peak velocity: r=0.072, p=0.458). Similar results were found using five other image analysis methods.
CONCLUSIONS: CT-derived aortic valve perivascular adipose tissue attenuation is not associated with AS disease severity, activity or progression suggesting that it has no value in the investigation and management of patients with AS.
Participants with HIV-1, orally received 150 mg (one 100 mg tablet + two 25 mg tablets per day) of GSK3640254 in a blinded setting. Open label dual NRTI background therapies were given as one tablet per day combination of 600 mg ABC / 300 mg 3TC OR 200 mg FTC / 25 mg TAF orally.
Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
PURPOSE:To accurately and efficiently screen an inhibitory monoclonal antibody to an enzymic antigen, by using physiological activity of the enzymic antigen as an index. CONSTITUTION:An animal is sensitized with an antigen to prepare cells capable of producing a monoclonal antibody to an enzymic antigen and the cells are fused to myelomatous cells to give a hybridoma (A) containing the monoclonal antibody. An anti-immunoglobulin antibody, etc., is immobilized to rabbit antimouse Ig sepharose (B) (shown in the figure). The components (A) and (B) are then mixed to immunologically adsorb the monoclonal antibody in the component (A) in the component (B) and afford an insoluble carrier (C) immobilizing the anti-immunoglobulin antibody adsorbing the monoclonal antibody. An enzymic antigen MDH (D), etc., is added to the component (C) and reacted to give a supernatant. The enzymic activity contained in the supernatant and component (C) is measured to give a bonded monoclonal antibody having adsorbed enzymic antigen activity (hereinafter referred to as activity), inhibitory monoclonal antibody having low activity and activated monoclonal antibody capable of remarkably increasing the activity.
The recommended dosage of tretinoin capsules is 22.5 mg/m2 orally twice daily until complete remission is documented. Discontinue tretinoin capsules 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first.

Discontinue tretinoin capsules if the t(15;17) translocation or PML/RARα fusion has not been identified [see Warnings and Precautions (5.3)]. Take tretinoin capsules with a meal. Swallow tretinoin capsules whole with water. Do not chew, dissolve, or open capsule. 

Do not take a missed dose of tretinoin capsules unless it is more than 10 hours until the next scheduled dose. If vomiting occurs after tretinoin capsules administration, do not take an additional dose, but continue with the next scheduled dose.
Provided is a technology that enables biological information relating to a subject to be processed appropriately and independently of on the subject. A biological information processing device according to the present embodiment includes a storage device, an estimation unit, an acquisition unit, and a correction unit. The storage unit stores biological information relating to a specified subject for a unit period including a plurality of times. The estimation unit estimates variable characteristics of the biological information based on the stored biological information relating to the specified subject. The acquisition unit acquires the biological information relating to the specified subject together with information indicating a measurement time of the biological information. The correction unit corrects the acquired biological information relating to the specified subject based on the information indicating the measurement time, which is acquired together with the biological information, and the estimated variable characteristics.
the invention discloses application of Bifonazole (Bifonazole) in preparing a medicament for preventing or treating influenza virus infection. Toxicity and anti-influenza activity and anti-inflammatory activity of bifonazole on cells were tested on a human monocyte U937 model. The results show that bifonazole has remarkable antiviral activity and can inhibit the release of proinflammatory cytokines induced by influenza infection. Bifonazole also has significant antiviral activity on the human lung epithelial cell line a549 and the canine kidney cell line MDCK. In a lethal mouse influenza infection model, the bifonazole can effectively reduce the virus titer in lung washing liquor of an infected mouse, delay the weight loss speed of the mouse, prolong the survival time of the mouse and improve the survival rate of the mouse. The bifonazole disclosed by the invention is a novel anti-influenza virus medicament with immunoregulation activity, has the advantages of good safety, high selection index, effective animal model experiment and the like, and can be used for developing medicaments for preventing or treating influenza virus infection.
Objective: To investigate the surgical strategy for chronic pancreatitis complicated with suspected malignant lesions in the pancreatic head and pancreatolithiasis in the distal pancreas. Methods: This is a retrospective cohort study. Clinical data from 11 patients with chronic pancreatitis who underwent pancreaticoduodenectomy combined with longitudinal pancreaticojejunostomy(PD-L) were retrospectively collected(PD-L group) from the Department of Hepatobiliary Surgery of the First Affiliated Hospital of Xi'an Jiaotong University between December 2021 and September 2023. All patients were male with an age of (49.0±11.2) years(range:32 to 70 years). Their primary preoperative diagnoses included pancreatic lesions, chronic pancreatitis, pancreatolithiasis, and dilatation of the pancreatic duct. Data from 248 patients who underwent pancreaticoduodenectomy(PD) during the same period were retrospectively collected(PD group). There were 157 males and 91 females in the PD group, with an age of (61.5±10.8) years(range:27 to 82 years). Among them, 87 cases were diagnosed as pancreatic cancer or chronic pancreatitis. The propensity score matching method was used to reduce confounding bias between the two groups. The caliper value of 0.1 was used and the 1∶4 nearest neighbor matching method was used for the matching. Comparisons between the two groups were made using the independent sample t test, Mann-Whitney U test or χ2 test,respectively. Results: After complete excision of the specimen during pancreaticoduodenectomy, the key surgical step of PD-L was longitudinal pancreaticojejunostomy in the remaining pancreas. Intraoperative blood loss in the PD-L group was lower than that in the PD group [M(IQR)](300(200)ml vs. 500(500)ml, respectively; P<0.05). Similarly, hospitalization days(21.0(7.0)days vs. 25.0(8.5)days) and postoperative hospitalization days(13.0(8.0)days vs. 17.0(5.0) days) were also lower in the PD-L group compared to the PD group (P<0.05). There were no significant differences in the operation time and postoperative complication rate between the two groups(P>0.05). In the PD-L group, the postoperative follow-up time was 5(5)months(range: 3 to 21 months). One case was lost for follow-up. Abdominal pain was relieved in 10 patients. Additionally, abdominal distension and steatosis were alleviated in 8 cases. Furthermore, 5 cases of diabetes mellitus showed improved control of HbA1c and fasting blood glucose levels after surgery. Conclusions: PD-L treatment can be used to treat chronic pancreatitis complicated by suspected malignant lesions in the pancreatic head and pancreatolithiasis in the distal pancreas. PD-L also has advantages in removing stones from the pancreatic duct and evaporation of pancreatic fluid. However, due to the single-center design and the small sample size of this study, further practice and long-term follow-up are still necessary.
Cancer is increasing in incidence and prevalence in the United Kingdom. Pain is the most frequent complication of cancer and cancer pain control is frequently suboptimal. Previous research has established several potentially modifiable reasons for suboptimal cancer pain management. These include: under-reporting of pain; inadequate communication about pain between patients and health care professionals ; inadequate assessment of pain by health care providers; inadequate analgesic prescribing; suboptimal adherence to prescribed analgesic regimens by patients; and failure to re-assess pain timeously.

Information and communication technology (ICT) is a term used to describe all digital technologies that facilitate the electronic capture, processing, storage, and exchange of information. ICT could offer innovative solutions to suboptimal cancer pain management. Technological solutions might include electronic diaries, available as applications or "apps", which could encourage pain self-monitoring by people with cancer, and prompt medical assessment when pain is poorly controlled. Accurate patient reported pain data could help professionals to adequately assess pain and might influence the patient-professional consultation. Feedback of adherence data to patients and carers might improve the way that medications are used. Electronic medication adherence devices are currently available which can capture data on analgesic utilisation and timing. This data might be useful for health care professionals to inform safe and timely adjustments of analgesic doses (i.e. is pain control poor because of inadequate analgesic dose or because of non-adherence to the prescribed regime?). The aim of the proposed study is to explore the desirability, feasibility, and practicalities of using ICT to improve cancer pain management The proposed study would seek the views of patients with cancer pain, their caregivers, and health care professionals, about using technology to help with cancer pain management. The study will investigate the acceptability of electronic pain diaries and electronic medication adherence devices to patients and health care professionals, barriers to using such technology, and how data generated from technology might be used by patients, caregivers, and health care professionals to improve cancer pain management. This study will form part of a programme of research and data from the proposed study will be used to inform the potential development of a technological intervention to improve the management of cancer pain in the community.
Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
PURPOSE: A composition for inducing dendritic cell maturation and a pharmaceutical composition containing dendritic cells for cancer therapy are provided to activate cytotoxic T cells or helper T cells. CONSTITUTION: A composition for inducing dendritic cell maturation contains a recombinant protein as an active ingredient, containing human body-derived CA9(carbonic anhydrase IX) protein and Acinetobacter baumannii coat protein A. The recombinant protein contains amino acids of sequence number 1 and 2, which are fused. A pharmaceutical composition for cancer therapy contains mature dendritic cells. The mature cells express CD40, CD80, CD86, MHC class I, and MHC class II. The cancer is renal cell carcinoma.
Prehistoric chewed pitch has proven to be a useful source of ancient DNA, both from humans and their microbiomes. Here we present the metagenomic analysis of three pieces of chewed pitch from Huseby Klev, Sweden, that were dated to 9,890-9,540 before present. The metagenomic profile exposes a Mesolithic oral microbiome that includes opportunistic oral pathogens. We compared the data with healthy and dysbiotic microbiome datasets and we identified increased abundance of periodontitis-associated microbes. In addition, trained machine learning models predicted dysbiosis with 70-80% probability. Moreover, we identified DNA sequences from eukaryotic species such as red fox, hazelnut, red deer and apple. Our results indicate a case of poor oral health during the Scandinavian Mesolithic, and show that pitch pieces have the potential to provide information on material use, diet and oral health.
Patients treated with DWP14012, Meloxicam will be enrolled. DDI will be evaluated.
Flexible use of a clinical decision support system is disclosed. A method is described for adapting method steps for finding results in a CT-based decision support method to an evaluation of an LDCT image dataset. In the method, a plurality of reference image data sets are acquired from a plurality of patients. In this case, the reference image dataset characterizes at least one CT image dataset from one of the plurality of patients and an LDCT dataset from the patient, respectively. Furthermore, the method steps for determining the result data are applied to different image data sets of the reference image data set. Comparing the result data with each other; and based on the result of the comparison, adapting the method steps for determining the result data to the determination of the result data from the LDCT image data set. A decision support method based on LDCT is also described. Furthermore, an adaptation device is described. A system for LDCT-based decision support is also described.